H E Parker1, A M Habib1, G J Rogers1, F M Gribble1, F Reimann1. 1. Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0XY, UK.
Abstract
AIMS/HYPOTHESIS: Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone with anti-apoptotic effects on the pancreatic beta cell. The aim of this study was to generate transgenic mice with fluorescently labelled GIP-secreting K cells and to use these to investigate pathways by which K cells detect nutrients. METHODS: Transgenic mice were generated in which the GIP promoter drives the expression of the yellow fluorescent protein Venus. Fluorescent cells were purified by flow cytometry and analysed by quantitative RT-PCR. GIP secretion was assayed in primary cultures of small intestine. RESULTS: Expression of Venus in transgenic mice was restricted to K cells, as assessed by immunofluorescence and measurements of the Gip mRNA and GIP protein contents of purified cells. K cells expressed high levels of mRNA for Kir6.2 (also known as Kcnj11), Sur1 (also known as Abcc8), Sglt1 (also known as Slc5a1), and of the G-protein-coupled lipid receptors Gpr40 (also known as Ffar1), Gpr119 and Gpr120. In primary cultures, GIP release was stimulated by glucose, glutamine and linoleic acid, and potentiated by forskolin plus 3-isobutyl-1-methylxanthine (IBMX), but was unaffected by the artificial sweetener sucralose. Secretion was half-maximal at 0.6 mmol/l glucose and partially mimicked by alpha-methylglucopyranoside, suggesting the involvement of SGLT1. Tolbutamide triggered secretion under basal conditions, whereas diazoxide suppressed responses in forskolin/IBMX. CONCLUSIONS/ INTERPRETATION: These transgenic mice and primary culture techniques provide novel opportunities to interrogate the mechanisms of GIP secretion. Glucose-triggered GIP secretion was SGLT1-dependent and modulated by K(ATP) channel activity but not determined by sweet taste receptors. Synergistic stimulation by elevated cAMP and glucose suggests that targeting appropriate G-protein-coupled receptors may provide opportunities to modulate GIP release in vivo.
AIMS/HYPOTHESIS: Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone with anti-apoptotic effects on the pancreatic beta cell. The aim of this study was to generate transgenic mice with fluorescently labelled GIP-secreting K cells and to use these to investigate pathways by which K cells detect nutrients. METHODS:Transgenic mice were generated in which the GIP promoter drives the expression of the yellow fluorescent protein Venus. Fluorescent cells were purified by flow cytometry and analysed by quantitative RT-PCR. GIP secretion was assayed in primary cultures of small intestine. RESULTS: Expression of Venus in transgenic mice was restricted to K cells, as assessed by immunofluorescence and measurements of the Gip mRNA and GIP protein contents of purified cells. K cells expressed high levels of mRNA for Kir6.2 (also known as Kcnj11), Sur1 (also known as Abcc8), Sglt1 (also known as Slc5a1), and of the G-protein-coupled lipid receptors Gpr40 (also known as Ffar1), Gpr119 and Gpr120. In primary cultures, GIP release was stimulated by glucose, glutamine and linoleic acid, and potentiated by forskolin plus 3-isobutyl-1-methylxanthine (IBMX), but was unaffected by the artificial sweetener sucralose. Secretion was half-maximal at 0.6 mmol/l glucose and partially mimicked by alpha-methylglucopyranoside, suggesting the involvement of SGLT1. Tolbutamide triggered secretion under basal conditions, whereas diazoxide suppressed responses in forskolin/IBMX. CONCLUSIONS/ INTERPRETATION: These transgenic mice and primary culture techniques provide novel opportunities to interrogate the mechanisms of GIP secretion. Glucose-triggered GIP secretion was SGLT1-dependent and modulated by K(ATP) channel activity but not determined by sweet taste receptors. Synergistic stimulation by elevated cAMP and glucose suggests that targeting appropriate G-protein-coupled receptors may provide opportunities to modulate GIP release in vivo.
Authors: Song Yan Wang; Maggie M-Y Chi; Lin Li; Kelle H Moley; Burton M Wice Journal: Am J Physiol Endocrinol Metab Date: 2002-12-30 Impact factor: 4.310
Authors: K Miyawaki; Y Yamada; H Yano; H Niwa; N Ban; Y Ihara; A Kubota; S Fujimoto; M Kajikawa; A Kuroe; K Tsuda; H Hashimoto; T Yamashita; T Jomori; F Tashiro; J Miyazaki; Y Seino Journal: Proc Natl Acad Sci U S A Date: 1999-12-21 Impact factor: 11.205
Authors: Matthew C Althage; Eric L Ford; Songyan Wang; Patrick Tso; Kenneth S Polonsky; Burton M Wice Journal: J Biol Chem Date: 2008-04-17 Impact factor: 5.157
Authors: Hyeung-Jin Jang; Zaza Kokrashvili; Michael J Theodorakis; Olga D Carlson; Byung-Joon Kim; Jie Zhou; Hyeon Ho Kim; Xiangru Xu; Sic L Chan; Magdalena Juhaszova; Michel Bernier; Bedrich Mosinger; Robert F Margolskee; Josephine M Egan Journal: Proc Natl Acad Sci U S A Date: 2007-08-27 Impact factor: 11.205
Authors: Anthony Sclafani; Damien S Glass; Robert F Margolskee; John I Glendinning Journal: Am J Physiol Regul Integr Comp Physiol Date: 2010-10-06 Impact factor: 3.619
Authors: Izumi Kaji; Toshihiko Iwanaga; Masahiko Watanabe; Paul H Guth; Eli Engel; Jonathan D Kaunitz; Yasutada Akiba Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-11-13 Impact factor: 4.052
Authors: R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross Journal: Pharmacol Rev Date: 2010-12 Impact factor: 25.468
Authors: John I Glendinning; Yonina G Frim; Ayelet Hochman; Gabrielle S Lubitz; Anthony J Basile; Anthony Sclafani Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-02-01 Impact factor: 3.619